All In Biotech

Drug Trial Radar · NCT07548177

Clinical Trials of Benmelstobart Injection Combined With Anlotinib Hydrochloride Capsules in the Treatment of Advanced or Unresectable Alveolar Soft Part Sarcoma

To Evaluate the Single-arm, Multi-center Phase II Clinical Trial of Benmelstobart Injection Combined With Anlotinib Hydrochloride Capsules in the Treatment of Advanced or Unresectable Alveolar Soft Part Sarcoma

Last checked: Nov 20, 2026Latest source record: Nov 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

33

Planned (sponsor's estimate)

Start

Apr 2, 2026

Primary completion

Dec 2028

Study completion Jun 2029

Sponsor

Sponsor type
Industry
First posted
Apr 23, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 14 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase II, single-arm, multicenter clinical study aimed at demonstrating the effectiveness of benmelstobart injection combined with anlotinib hydrochloride capsules in patients aged 14 years or older with advanced or unresectable alveolar soft part sarcoma by evaluating the objective response rate (IRC).

Conditions

  • Alveolar Soft Part Sarcoma

Interventions

  • Benmelstobart injection combined with Anlotinib hydrochloride capsuleDrug

    Benmelstobart is a PD-L1 immunosuppressant. Anlotinib hydrochloride is a muti-target tyrosine kinase inhibitor.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Objective response rate (IRC assessment)Time frame: The period from baseline to the end of the trial is expected to be 32 months.

Locations

15 sites in 1 country. Site status is shown where the registry gives one.

  • Beijing Cancer Hospital

    Beijing, Beijing Municipality, China · Recruiting

  • The First Affiliated Hospital of Army Medical University of the People's Liberation Army of China

    Chongqing, Chongqing Municipality, China · Not yet recruiting

  • Sun Yat-sen University Cancer Center

    Guangdong, Guangdong, China · Not yet recruiting

  • Harbin Medical University Cancer Hospital

    Harbin, Heilongjiang, China · Not yet recruiting

  • Henan Cancer Hospital

    Zhengzhou, Henan, China · Not yet recruiting

  • Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

    Wuhan, Hubei, China · Not yet recruiting

  • Xiangya Hospital of Central South University

    Changsha, Hunan, China · Not yet recruiting

  • The first hospital of Jilin University

    Changchun, Jilin, China · Not yet recruiting

  • Shandong First Medical University Affiliated Tumor Hospital

    Jinan, Shandong, China · Not yet recruiting

  • Shanghai General Hospital

    Shanghai, Shanghai Municipality, China · Not yet recruiting

  • West China Hospital of Sichuan University

    Chengdu, Sichuan, China · Not yet recruiting

  • Tianjin Medical University Cancer Institute & Hospital

    Tianjin, Tianjin Municipality, China · Not yet recruiting

  • Xinjiang Medical University Affiliated Cancer Hospital

    Ürümqi, Xinjiang, China · Not yet recruiting

  • The Second Affiliated Hospital, Zhejiang University School of Medicine.

    Hangzhou, Zhejiang, China · Not yet recruiting

  • Zhejiang Cancer Hospital

    Hangzhou, Zhejiang, China · Not yet recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.